Mutations in the transforming growth factor b type II receptor (TGFbRII) have been found in various malignant tumors, suggesting that loss of TGFb signaling plays a causal role in late-stage cancer development. To test whether loss of TGFbRII is involved in early-stage carcinogenesis, we have generated transgenic mice expressing a dominant negative TGFbRII (DbRII) in the epidermis. These mice exhibited an increased susceptibility to chemical carcinogenesis protocols at both early and late stages. In the current study, parameters for cell cycle progression and chromosome instability were analysed in DbRII tumors. DbRII papillomas showed an increased S phase in¯ow cytometry. Bromodeoxyuridine (BrdU) labeling and mitotic indices in DbRII papillomas also showed a threefold increase compared to papillomas developing in non-transgenic mice. When papillomas further progressed to squamous cell carcinomas (SCC), both control and DbRII SCC showed similar BrdU labeling indices and percentages of S phase cells. However, DbRII SCC cells showed a sixfold increase in the G2/M population. Mitotic indices in DbRII SCC also showed a threefold increase compared to non-transgenic SCC. Consistent with a perturbed cell cycle, DbRII papillomas and SCC showed reduced expression of the TGFb target genes p15 (INK4b), p21 (WAF-1) and p27 (Kip1), inhibitors of cyclin-dependent kinases (cdks). However, most DbRII papilloma cells exhibited normal centrosome numbers, and DbRII SCC exhibited a similar extent of centrosome abnormalities compared to control SCC (35 ± 40% cells). Most of DbRII SCC exhibited diploid chromosome pro®les. These data indicate that inactivation of TGFbRII accelerates skin tumorigenesis at early stages by the acceleration of loss of cell cycle control, but not by increased chromosome instability. Oncogene (2000) 19, 3623 ± 3631.
Introduction
The transforming growth factor b (TGFb) is a potent growth inhibitor in epithelial tissues (for reviews, see Filmus and Kerbel (1993) ; Fynan and Reiss (1993) ; Satterwhite and Moses (1994) ). It is believed that TGFb acts as a tumor suppressor, since malignant epithelial tumors develop mechanisms of escaping from TGFbinduced growth inhibition (Filmus and Kerbel, 1993; Fynan and Reiss, 1993; Satterwhite et al., 1994) . The functions of TGFb are mediated by the tetraheteromers of the type I and II TGFb receptors (TGFbRI and TGFbRII, (Derynck, 1994) ). Upon ligand binding, the intrinsic serine/threonine kinase of TGFbRII phosphorylates TGFbRI to activate its serine/threonine kinase activity (Wrana et al., 1994; Chen and Weinberg, 1995) . This activated receptor complex transduces TGFb signals (Feng et al., 1995) . Deletion of the serine/threonine kinase domain of TGFbRII produces a dominant negative form (DbRII), which is able to block the growth inhibitory function of TGFb in vitro (Chen et al., 1993; Wieser et al., 1993) and in transgenic animals (Wang et al., 1997b; Bottinger et al., 1997; Gorska et al., 1998) , suggesting that TGFbRII is required to mediate the growth inhibitory eect of TGFb. Mutations in TGFbRII were initially detected in TGFb-resistant cancer cell lines (Markowitz et al., 1995; Myero et al., 1995; Carcamo et al., 1995) . Similar mutations have then been reported in primary cancers of colon Takenoshita et al., 1997; Iacopetta et al., 1998; Lu et al., 1998) , head and neck (Lu et al., 1995 (Lu et al., , 1998 Wang et al., 1997a) , ampulla (Imai et al., 1998) , and pancreas (Venkatasubbarao et al., 1998) . These data suggest that inactivation of TGFbRII might be one mechanism by which epithelial tumor cells escape from TGFb-induced growth inhibition and progress to malignancy. To test this hypothesis in the skin, we have generated transgenic mice expressing DbRII in the epidermis, utilizing a truncated mouse loricrin vector (ML.DbRII). ML.DbRII mice exhibit a marked hyperplasia/hyperkeratosis at birth, suggesting that the DbRII can block TGFb mediated growth inhibition in the epidermis (Wang et al., 1997b) . This is further supported by the fact that primary keratinocytes isolated from the epidermis of ML.DbRII transgenic mice were resistant to exogenous TGFb1 induced growth inhibition (Wang et al., 1997b) . When ML.DbRII mice were subjected to a two-stage chemical carcinogenesis protocol, they exhibited an increased susceptibility compared to non-transgenic mice, with greatly accelerated benign papilloma formation, malignant conversion and metastasis (Go et al., 1999) . In addition, topical application of the tumor promoter TPA to ML.DbRII mice elicited papillomas which had a low rate of c-ras Ha mutations (Go et al., 1999) , suggesting that DbRII can play an initiating role in chemical carcinogenesis. These data indicate that blocking TGFb signaling plays a role in accelerating carcinogenesis at both early and late stages. An analysis of the mechanisms by which DbRII accelerates carcinogenesis at later stages revealed that ML.DbRII tumors exhibited increased angiogenesis, which was consistent with the rapid progression of these tumors to metastasis (Go et al., 1999) . Here we provide in vivo evidence that aberrant cell cycle progression contributes signi®cantly to accelerated skin carcinogenesis at early stages.
Results

ML.DbRII tumor cells exhibit increased cell cycle progression
Tumors in ML.DbRII and control mice were induced by dimethylbenz [a] anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA), as previously described (Go et al., 1999) . Papillomas and early-stage SCC (15 ± 25 weeks and 30 ± 40 weeks after DMBA initiation. respectively) were biopsied. To determine if DbRII tumors possess aberrant cell cycle progression,¯ow cytometry was utilized to identify changes in DNA content in tumor cells from ML.DbRII and control mice. Cell populations in normal keratinocytes from neonatal mice consisted of 88.7+2.0% in the G1 phase, 6.3+0.8% in the S phase, and 4.9+1.8% in the G2/M phase (Table 1) . Consistent with our previous report that DbRII epidermis exhibited 2.5-fold increase in BrdU labeling compared to non-transgenic epidermis (Wang et al., 1997b) , DbRII epidermis showed *twofold increase in the S phase population (14.1+1.5%, Table 1 ). In chemically-induced papillomas arising from non-transgenic mice, the S population is 6.3+3.4% ( Figure 1 , Table 1 ) similar to that in neonatal epidermis, which is *threefold higher than that in the adult epidermis (Bertsch and Marks, 1982) . DbRII papillomas exhibited *twofold higher S phase (11.7+2.9%, Figure 1 , Table   1 ). In chemically-induced SCC of non-transgenic mice, the S population increased to 15.8+5.8% Table 1 ). SCC in DbRII mice displayed an S population (10.9+4.2%) similar to control SCC, but a sixfold increase in the G2/ M population (23.3+19%) compared to that of nontransgenic SCC (4.1%, Table 1 ). Thus, the G1 population in DbRII SCC was reduced to 59.4+18% ( Figure 1 , Table 1 ). Out of seven ML.DbRII SCC analysed, only one contained tetraploid cells (Figure 1 , Table 1 ).
DbRII papillomas exhibit higher Bromodeoxyuridine (BrdU) labeling
To further con®rm changes in DNA synthesis in DbRII tumors, in vivo BrdU labeling was performed on chemically-induced papillomas and SCC. Since the BrdU index measures the S phase cells among cells with proliferative potential (i.e., basal cells in normal epidermis) instead of the entire tumor cell population, this method is more sensitive than¯ow cytometry in determining the changes in DNA synthesis. The same size of tumors (5 mm in diameter for papillomas and SCC) from each group were excised 1 h after BrdU injection. The labeling index of DbRII papillomas was 61+18 cells/mm basement membrane, (n=5, Figure 2 ), threefold higher than that of control papillomas (20+3.5 cells/basement membrane, n=6, P50.0001, Figure 2 ). When papillomas progressed to SCC, BrdU labeling indices were increased to 35+11 cells/mm basement membrane for control SCC ( Figure 2) ; however, BrdU labeling in DbRII SCC (40+9.8 cells/ basement membrane, Figure 2 ) did not show a further increase in comparison with either DbRII papillomas or control SCC. These results are consistent with thē ow cytometry pro®les of these tumors. We also examined the rate of apoptosis in both DbRII and non-transgenic tumors, but it was not altered (data not shown).
DbRII tumors exhibit higher mitotic indices
The G2/M phase in¯ow cytometry does not distinguish between the cells which are arrested in Table 1 DNA content of tumor cells determined by¯ow cytometry Although DbRII tumors progress to metastasis as early as tumors harboring a gain-of-function p53 mutant (p53 m , (Wang et al., 1998a,b) ), histologically they dier from p53 m tumors. DbRII SCC were welldierentiated and usually contained a single nucleus ( Figure 2 , (Go et al., 1999) ), whereas p53 m tumors were poorly dierentiated and exhibited multiple nuclei (tetra-or multi-ploidity) (Wang et al., 1998a,b) . However, DbRII tumors exhibited increased mitotic indices compared to non-transgenic controls ( Figure 3 ). The mitotic index in DbRII papillomas averaged 2.6+0.7 (n=10). which was threefold higher than papillomas in the control group (0.9+0.3, n=10, P50.0001). When papillomas further progressed to SCC, the mitotic index in the nontransgenic group increased to 1.24+0.1 (n=10, P50.05 compared to non-transgenic papillomas). However, dierent from BrdU labeling indices that both control and DbRII SCC exhibited a similar extent increase, the mitotic index in DbRII SCC was three-fold higher (4.6+1.5, n=10) than control SCC (P50.0001 compared to non-transgenic SCC). This result indicates that some DbRII tumor cells also escaped from G2 arrest and entered the mitotic phase.
DbRII tumor did not exhibit a significant increase in centrosome abnormalities
Although¯ow cytometry pro®les did not show obvious aneuploid cell populations in the majority of ML.DbRII tumors, it is still possible that tumors contain a small portion of aneuploid cells or aneuploid cells with a chromosome mode close to 40 (Aldaz et al., 1987; Conti et al., 1986) . Furthermore,¯ow cytometry pro®les cannot exclude chromosome instabilities resulting from unequal segregation, breaks and rearrangement of chromosomes. Therefore, we examined centrosomes in tumors, a more sensitive marker of chromosome instability (Brinkley, 1985) . Because centrosomes duplicate only once during the cell cycle, excessive duplication, as indicated by more than two centrosomes in the cytoplasm, would result in unequal segregation and breaks of chromosomes (Brinkley, 1985) . In non-transgenic papillomas examined, 97% of tumor cells contained a normal number of centrosomes (1 or 2), and only 3% of tumor cells exhibited three centrosomes/cell (Figure 4) . DbRII papillomas showed an increase in centrosome abnormality, with 12% of tumor cells containing three centrosomes/cell ( Figure 4 , Table 2 ). However, 88% centrosome numbers, and none of the cells contained 54 centrosomes/cell. This result is in sharp contrast to the previous reports on centrosome numbers in papillomas containing the p53 m transgene, in which 30% of tumor cells showed three centrosomes/cell and 45% contained 54 centrosomes/cell (Wang et al., 1998a,b) . Interestingly, one DbRII papilloma biopsied from transgenic mouse c2849, showed signi®cant increase in abnormal centrosome numbers. The remaining cells of this tumor, which were not observed grossly, later developed to an SCC and exhibited aneuploid cell populations ( Figure 1 , Table 1 ). In this case, 47% of the tumor cells showed abnormal centrosomes, with most of these cells containing more than four centrosomes ( Figure 4 , Table 2 ). When papillomas progressed to SCC, both control and DbRII tumors exhibited increased abnormal centrosome numbers with a similar rate (41% in DbRII SCC and 35% in control SCC, Figure 4 , Table 2 ). Most of these abnormal cells contained three centrosomes, and cells containing four or more centrosomes were rare. Again, the DbRII c2849 SCC that exhibited a tetraploid cell population ( Figure 1 , Table 1 ), exhibited abnormal centrosome numbers in 50% tumor cells, with most cells containing four or more centrosomes ( Figure 4 , Table 2 ). These data indicate that although both DbRII and control SCC exhibit chromosome instability, DbRII SCC did not exhibit a signi®cant increase in chromosome instability.
DbRII tumors exhibit reduced p15 and p21 expression, and loss of p27 protein It has been reported that TGFb induces growth inhibition via the elevation of the cdk inhibitors p15 (INK4b) (Hannon and Beach, 1994) and p21 (WAF-1) (Datto et al., 1995) at the transcription level, and p27 (Kip1) at the post-translation level (Polyak et al., 1994) . To determine whether the DbRII accelerates carcinogenesis by blocking TGFb-induced elevation of these cdk inhibitors, RNase protection assay (RPA) was performed to determine expression levels of p15 (INK4b) and p21 (WAF-1) transcripts in chemicallyinduced tumors of both DbRII and control mice. Expression of p15 was reduced by 2 ± 3-fold in DbRII papillomas and 3 ± 4-fold in SCC compared to nontransgenic papillomas and SCC, respectively ( Figure  5a ). In addition, expression of p16 (INK4a), a family member of p15, did not show changes in tumors (data not shown). Expression of p21 in DbRII papillomas was also reduced by twofold in comparison with nontransgenic papillomas (Figure 5a ). While expression of p21 in DbRII SCC was at a level similar to that in ML.DbRII papillomas, some of the non-transgenic SCC also began to show a reduction in p21 expression (Figure 5a ). Western analysis was performed to Oncogene Aberrant cell cycle progression in tumors expressing DbRII C Go et al determine p27 protein levels in control and transgenic tumors. Expression of p27 in DbRII papillomas was undetectable, whereas papillomas from non-transgenic mice still retained p27 expression (Figure 5b ). Both DbRII SCC and non-transgenic SCC have exhibited a complete loss of p27 protein (Figure 5b ).
Discussion
The detection of mutations in TGFbRII in human cancer suggests that inhibition of TGFb signaling may be an important mechanism in malignant progression of epithelial tumors. To test this in an in vivo model, we previously performed chemical carcinogenesis experiments on ML.DbRII transgenic mice and showed that blocking TGFb signaling plays a role in accelerating skin carcinogenesis at both early and late stages (Go et al., 1999) . In the present study we have focused on the analysis of mechanisms of DbRIIinvolved in the earlier stages of carcinogenesis.
Acceleration of aberrant cell cycle progression appears to be an important mechanism whereby DbRII accelerates tumorigenesis
The role of TGFb in cell cycle control has been suggested to be essential to its tumor suppressive eect (Satterwhite and Moses, 1994) . In vitro studies have demonstrated that TGFb arrests cell cycle progression in late G1, via the activation of several cyclindependent kinase (cdk) inhibitors (Polyak, 1996; Satterwhite and Moses, 1994) . To determine whether blocking TGFbRII signaling results in premature cell cycle progression in vivo,¯ow cytometry was used to analyse cell cycle populations of DbRII epidermis and tumor cells. DbRII epidermis and papillomas showed a *twofold increase in S phase compared to those of non-transgenic epidermis and papillomas, respectively. In SCC, DbRII tumors exhibited a lower G1 population and a sixfold increase in the G2/M population compared to non-transgenic tumors ( Figure   1 , Table 1 ). Consistent with the¯ow cytometry data, BrdU labeling was increased *twofold in DbRII epidermis (Wang et al., 1997b) and *threefold papillomas (Figure 2 ). In addition, DbRII tumors also exhibited increased mitotic indices (Figure 3 ). These results indicate that more cells in DbRII tumors have escaped from G1 arrest and have entered into the G2/ M phase. Although the detailed mechanisms remain to be determined, the failure in G1 arrest in DbRII tumors, can be attributed at least in part to the earlier reduction of p15, p21 and p27 in DbRII papillomas ( Figure 5 ). All three of these cdk inhibitors are implicated by in vitro studies to be downstream targets of TGFb, and mediate TGFb-induced growth inhibition (Hannon and Beach, 1994; Datto et al., 1995; Polyak et al., 1994) . Interestingly, Nagase et al. (1999) have recently identi®ed two skin tumor resistant alleles Skts2 and Skts10 which lie near the loci of p21 and p27, respectively. Our current data further suggest a tumor suppressive role of these cdk inhibitors in skin carcinogenesis. Consistent with the report of Nagase et al. (1999) , we observed a loss of expression of p21 and p27 when non-transgenic papillomas converted to malignant SCC ( Figure 5 ). At this stage, tumors begin to lose TGFbR and the signaling Smads (our unpublished data). Therefore, the loss of endogenous TGFb signaling at this stage is coincident with the loss of these two cdk inhibitors. Collectively, our data provide in vivo evidence that loss of TGFb signaling results in deregulation of these cdk inhibitors. Therefore, in future studies, it would be of interest to determine which speci®c cdks are responsible for DbRII-induced acceleration of cell cycle progression. The candidates of these cyclin-cdk complexes include cyclin D-cdk4/6 (Hannon et al., 1994; Datto et al., 1995; Polyak et al., 1994) , cyclinA-cdk2 (Geng and Weinberg, 1993) and cyclin E-cdk2 (Geng and Weinberg, 1993; Nagahara et al., 1999) . In addition, it would be worthwhile to examine other upstream modulators of cdks which are suggested to be TGFb targets, e.g., Rb (Murphy et al., 1991) , myc (Murphy et al., 1991) , and cdc25 (Iavarone and Massague, 1997) .
Genetic instability in DbRII tumors may be a consequence of the accelerated aberrant cell cycle progression
The propensity of DbRII papillomas to undergo a rapid malignant conversion, suggests a potential role of DbRII in genomic instability. Genomic instability occurs in two dierent forms (Cahill et al., 1998) : microsatellite instability which is associated with an increased mutation rate but maintains diploidy of tumor cells; and chromosome instability which induces aneuploidy of tumor cells. Mutations in TGFbRII have been shown to occur as a result of microsatellite instability (Markowitz et al., 1995; Myero et al., 1995) . Since chromosome abnormalities are a hallmark of malignant progression in chemically-induced skin tumors (Aldaz et al., 1987; Conti et al., 1986) , we were interested in determining whether DbRII tumors possessed increased chromosome instability. The DNA content and centrosome numbers of DbRII tumors were examined in benign papillomas and early stage SCC. Six of the seven DbRII SCC analysed showed diploid DNA content, and only one tumor exhibited a typical aneuploid pro®le (Table 1 ). In Figure 5 (a) Changes in expression of p15 and p21 in DbRII tumors. NL: non-transgenic control; Pap: papillomas. RNase protection assays were performed using speci®c riboprobes as labeled in each panel. Note that DbRII papillomas and SCC exhibited lower p15 expression levels in comparison with NL papillomas and SCC, respectively. DbRII papillomas also showed lower p21 expression compared to NL papillomas. Expression of p21 in DbRII SCC showed a slightly lower level than DbRII papillomas, and two of NL SCC also showed decrease in p21 expression compared to NL papillomas. (b) Western analysis of p27. Note the complete loss of the p27 protein in DbRII papillomas and SCC as well as in NL SCC
Aberrant cell cycle progression in tumors expressing DbRII C Go et al contrast to our current results, the study by Conti et al. (1986) showed chromosome banding identi®ed aneuploid cells after 30 or 40 weeks of promotion with a chromosome mode of 41 ± 47. These aneuploid cells also formed the stem cell lines of these tumors after selection in culture (Conti et al., 1986 ). In our current study, tumor samples were subjected to¯ow cytometry without selection in culture. Therefore, tumors which contained a small portion of aneuploid cells or aneuploid cells with a chromosome mode similar to that in the above study would not be detected by¯ow cytometry. We then examined the number of centrosomes in tumor cells, since this is a more sensitive marker for chromosome instability. Interestingly, most DbRII papillomas showed normal centrosome numbers in the majority of tumor cells. Only one DbRII papilloma that showed aberrant centrosome numbers, its remaining biopsy developed aneuploid cells in SCC. This result is in sharp contrast to tumors harboring the p53 m transgene, which possess a high proportion of cells with multiple centrosome numbers in benign papillomas (Wang et al., 1998a,b) and aneuploid cells with a chromosome mode average of 80 to 130 in SCC (Li et al., 1997, and our unpublished data) . Taken together, results from both of these studies suggest that centrosome numbers in benign papillomas may be an indicator to predict whether tumors will develop chromosome instability. Consistent with previous reports that malignant skin tumors develop chromosome instabilities (Conti, et al., 1986) , both DbRII and control groups SCC exhibited abnormal centrosome numbers in 35 ± 40% of cells, although the overall DNA content pro®les of these tumors still showed diploid chromosome pro®les. However, DbRII did not cause a further increase in chromosome instability compared to non-transgenic tumors. Our current study is in contrast to a recent report by Glick et al. (1999) , which showed that v-ras Ha transduced keratinocytes which were co-transfected with a DbRII construct rapidly developed aneuploidy. Therefore, it appears that the mechanisms involved in regulating genomic stability in vivo are more complicated, and other tumor suppressive mechanisms may be activated to compensate for loss of TGFb signaling in DbRII tumors. In addition, the lack of increase in aneuploidy in DbRII tumors suggests that DbRII may not directly perturb G2 or mitotic spindle checkpoints, which is also re¯ected by the signi®cant increase in the G2/M phase in DbRII tumors. However, since DbRII tumor cells have escaped from the DNA damage checkpoint (G1), accumulation of such damage may eventually increase chromosome instability. Taken collectively, our current in vivo data may link DbRII-induced cell cycle abnormalities and genetic instability together, since mutations resulting from either subtle chromosomal damage or microsatellite instability would be further augmented by premature cell cycle progression.
It is noteworthy that the tumorigenesis kinetics in ML.DbRII mice is very similar to that of transgenic mice expressing p53 m in the epidermis (Wang et al., 1998a,b; Go et al., 1999) , however the actual molecular events leading to tumor progression were quite distinct between these two models. First, in contrast to p53 m tumors that exhibited signi®cant chromosome instability (Wang et al., 1998a,b) , ML.DbRII tumor cells showed a large G2/M population, but rarely aneuploid cells. Therefore, perturbation of cell cycle control appears to be a primary mechanism whereby DbRII accelerates tumorigenesis; whereas chromosome instability may be a direct eect of p53 m . Secondly, increased angiogenesis in ML.DbRII tumors correlated with their earlier metastatic invasion (Go et al., 1999) ; whereas p53 m tumors did not exhibit an increase in angiogenesis (Wang et al., 1998b) . These results highlight the importance of using transgenic models to investigate dierent molecular mechanisms leading to distinct alterations in cancer development.
Materials and methods
Chemical carcinogenesis protocols
Ten-week-old ML.DbRII heterozygous mice and their nontransgenic littermates were divided into groups (30 mice in each group) for topical treatment with DMBA/TPA or vehicle (acetone) alone. The back skin of each mouse was carefully shaved 2 days before the treatment. Mice were treated ®rst with a sub-carcinogenic dose of DMBA (50 mg in acetone), followed by 20 weeks of TPA, 5 mg (in acetone)/ week, starting at 1 week after DMBA initiation. Tumors biopsied in this study were removed at 15 ± 25 weeks and 30 ± 40 weeks after DMBA initiation for papillomas and SCC, respectively.
Tissue histology
Biopsied tumors were ®xed in 10% neutral-buered formalin at 48C overnight, embedded in paran, sectioned to 6 mm thickness, and stained with hematoxylin and eosin (H & E).
Flow cytometry of tumor cells
Epidermal keratinocytes from neonatal non-transgenic control and DbRII mice were prepared as previously described (Wang et al., 1997b) . Tumor-bearing mice were sacri®ced and tumors were excised, cut to 1 ± 2 mm pieces, stirred in DMEM medium (Biowittaker, MA, USA) containing 0.35% collagenase (GIBCO) at 378C for 30 min. The supernatant of the collagenase crude preparation, containing blood, necrotic cells, ®broblasts, and squames was discarded. Tissue fragments were then stirred twice in 1% trypsin-PBS (GIBCO) at 378C for 30 min. Tumor cells were collected by ®ltering each trypsinized crude preparation through a 50 mm nylon mesh, and centrifugation at 200 g for 4 min. Each trypsinized cell fraction was split into two parts: one was cultured in 50% ®broblast conditioned medium (Greenhalgh et al., 1989) with 0.05 mM Ca 2+ , another was washed with PBS, ®xed in cold methanol for 10 min, and stored in PBS at 48C for¯ow cytometry. After con®rming by cell culture that cells in the trypsinized fraction were tumor cells originating from keratinocytes, 2610 6 methanol ®xed cells were stained with propidium iodide (50 mg/ml) in the presence of 100 mg/ ml RNase A at 378C for 30 min, and analysed by¯ow cytometry. The samples were run on a Coulter Electronics Pro®le II. The propidium iodide was excited with a 488 nm laser line at 15 mW power. The¯uorescent emission was collected in a PMT masked with a 575 nm band pass ®lter. All samples were gated on Forward Angle Light Scatter and a mitotic discriminator which consists of the integrated signal plotted against the peak signal. The resultant events are displayed on a linear scale so that G2 is in twice the channel of G0/G1. Normal keratinocytes, isolated from neonatal epidermis, are used to determine peaks of G0/G1 and G2/M phase in each assay. Aneuploid tumors met the following criteria: two individual or asymmetric G0/G1 peaks with two well-de®ned G2/M peaks. 10 000 events were collected to provide adequate statistical validity. Histograms were analysed using the ModFit LT software (Verity Software House, Topsham, ME, USA).
BrdU uptake and staining
Tumor-bearing mice were injected (i.p.) with BrdU 125 mg/ kg in 0.9% NaCl. The same size of DMBA/TPA-induced tumors from ML.DbRII and non-transgenic control mice were biopsied 1 h after the injection, ®xed and processed as previously described (Greenhalgh et al., 1996) . Sections were incubated with FITC-conjugated monoclonal antibody to BrdU (Becton-Dickinson) and a guinea-pig antiserum to mouse keratin 14 (K14), which reacts with the epithelial component of papillomas. K14 was visualized by biotinylated anti-guinea-pig IgG (Vector) and Streptavidin-Texas Red (GIBCO). BrdU labeled cells were counted under 106ocular and 206objective lenses. Consecutive ®elds were counted throughout the entire tissue section. The labeling index was expressed as the mean of BrdU-positive cells/mm basement membrane+s.d.
Apoptosis assays
Apoptosis was evaluated using a Deoxynucleotidetransferase Uridine End Labeling (TUNEL) assay with the TACS kits from Trevigen Inc. (Gaithersburg, MD, USA). Tumors were ®xed in 10% neutral buered formalin, sectioned, and visualized by diaminobenzidine.
Mitotic Index (MI)
Criteria and the counting method for mitotic cells were used as described by van Diest et al. (1992) . Brie¯y, 106ocular and 406objective lenses of a light microscope were used (high power ®elds, HPFs). In the counting area mitotic ®gures were counted in 10 consecutive HPFs starting at the spot within the counting area with the highest density of mitotic ®gures, avoiding ®elds with necrosis or in¯ammation and ®elds containing less than 50% tumor cells. The average number of mitotic cells/HPFs from 10 HPFs is determined as MI. The MI for each group (10 tumors) was averaged from individual MI.
Centrosome localization
Frozen tumors were sectioned to 30 mm thickness and ®xed with 3.7% formaldehyde after 2 min treatment with 0.5% Triton X-100. Samples were then incubated with human autoantiserum PCM-1, that recognizes centrosomes in mammalian cells (a gift from Dr Ron Balczon), and rabbit anti-keratin K14, which reacts with the epithelial component of tumors, followed by incubation with FITC-conjugated goat anti-human IgG and Texas Red conjugated goat antirabbit IgG. The sections were then visualized using a laser scanning microscope (Molecule Dynamics Inc.). Four to ®ve tumors in each group were examined, and 200 cells in each tumor were counted for centrosome numbers.
RNase protection assays
Total RNA was isolated from chemically-induced tumors with RNAzol B (Tel-Test, Inc.) as previously described (Wang et al., 1998b) . RNase protection assays (RPA) were performed using the RPA II kit (Ambion, TX, USA) and 32 Plabeled riboprobes. Riboprobe speci®c for p21 (WAF-1) was generated as previously described (Wang et al., 1998a) . The SmaI/SacII fragment of murine p15 (INK4b) cDNA (kindly provided by Dr Charles J Sherr) was subcloned into pGem 5 (Promega), and linearized with ApaI as the template of the p15 riboprobe. The XhoI fragment of murine p16 (INK4a) cDNA (provided by Dr Charles J Sherr) was subcloned into the SalI site of pGem 5, and linearized at the internal AsuII site of p16, to produce a 400 bp fragment of the p16 riboprobe. The intensity of protected bands was determined by densitometric scanning of X-ray ®lms.
Western analysis for p27
Total proteins of tumors were extracted as described (Wang et al., 1997b ). An equal amount of protein from each sample was separated by electrophoresis on a 12.5% SDS ± PAGE gel and transferred onto a nitrocellulose membrane. The blot was blocked by 5% non-fat milk in T-TBS (0.1% Tween20-TBS), at room temperature for 1 h. The goat anti-mouse p27 polyclonal antibody (Santa Cruz) was applied to the blot with 0.4 mg/ml in the blocking buer, at 48C for overnight. The blot was washed twice with T-TBS for 10 min, and incubated with 1 : 500 peroxidase conjugated rabbit anti-goat IgG (Sigma) at room temperature for 1 h. After washing as described above, the ECL detection system (Amersham) was used to visualize p27. To con®rm equal loading, the blot was stripped with ImmunoPure IgG Elution Buer (Pierce, Rockford, IL, USA) and re-screened with a sheep anti-mouse K14 antibody.
